Cholangiocarcinoma: Molecular targeting strategies for chemoprevention and therapy

@article{Sirica2005CholangiocarcinomaMT,
  title={Cholangiocarcinoma: Molecular targeting strategies for chemoprevention and therapy},
  author={A. Sirica},
  journal={Hepatology},
  year={2005},
  volume={41}
}
Cholangiocarcinomas are devastating cancers that are increasing in both their worldwide incidence and mortality rates. The challenges posed by these often lethal biliary tract cancers are daunting, with conventional treatment options being limited and the only hope for long‐term survival being that of complete surgical resection of the tumor. Unfortunately, the vast majority of patients with cholangiocarcinoma typically seek treatment with advanced disease, and often these patients are deemed… Expand
Molecular Targets in Biliary Carcinogenesis and Implications for Therapy.
TLDR
A comprehensive review of targeted therapies in biliary tract cancers was undertaken to present emerging evidence from laboratory and/or molecular studies as they translate to clinical trials and outcomes. Expand
Biliary tract carcinoma: clinical perspectives on molecular targeting strategies for therapeutic options
TLDR
The outcomes of recent studies have revealed, in detail, the molecular mechanism of carcinogenesis and tumor progression of BTC, and these studies have exploited select molecular targets that could significantly impact the clinical outcome. Expand
Pathogenesis and Therapeutic Targets of Cholangiocarcinoma
TLDR
A detailed review of the pathogenesis of cholangiocarcinoma and its relevance in molecular targets for potential therapies in cholanigans, and the understanding of the prognostic difference within this disease is begun. Expand
The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer
TLDR
There remains an urgent need for new approaches and models to improve management of this insidious and devastating disease and a bedside-to-bench approach to discussing cholangiocarcinoma is taken and research opportunities for the future are outlined. Expand
Diagnosis and management of cholangiocarcinoma
TLDR
Advances in understanding the pathogenesis of CC, including the role of oncogenes, inflammation-mediated genomic instability, and interleukin-6/STAT-3 signaling pathways, may allow development of new diagnostic and prognostic markers and targets for CC therapy. Expand
Cholangiocarcinoma development: The resurgence of bile acids
TLDR
It is proved that taurocholic acid (TCA) exerts proproliferative effects on rat and human cell lines that are blocked by treatment with JTE-013 or by shRNA knockdown of S1PR2, a new bile acid receptor identified recently. Expand
Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009.
TLDR
Magnetic resonance imaging/magnetic resonance cholangiopancreatography, positron emission tomography scan, endoscopic ultrasound and computed tomography scans are the most frequently used modalities for diagnosis and tumor staging. Expand
Reappraisal of the Therapeutic Role of Celecoxib in Cholangiocarcinoma
TLDR
It is concluded that short-term high dose celecoxib may be a promising therapeutic regimen for CCA, but its clinical application still needs more studies to prove its safety. Expand
The role of microRNAs in liver cancer
TLDR
An obvious need emerges for the discovery of new biomarkers to understand the events leading to hepatocarcinogenesis, to relate different phenotypes with differences in clinical behavior and prognosis, and, if possible, to predict response rates to adjuvant therapeutic modalities or to establish novel mechanism-based treatments for hepatic tumors. Expand
Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma.
  • Tong Wu
  • Medicine
  • Biochimica et biophysica acta
  • 2005
TLDR
The recently delineated interplay between COX-2-derived PG signaling and other growth-regulatory pathways, such as EGFR, ErbB2, IL-6/GP130, HGF/Met, TGF-beta/Smad, and iNOS is expected to provide important therapeutic implications. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 144 REFERENCES
A Review and Update on Cholangiocarcinoma
TLDR
This review discusses epidemiology, etiologic factors, molecular pathogenesis, diagnosis, staging, and treatment of cholangiocarcinoma, with particular focus on recent studies into the cellular and molecular pathogenic of the disease, recent chemotherapy trials, and newer methods of staging and screening. Expand
Diagnosis and treatment of cholangiocarcinoma
TLDR
Liver transplantation for unresectable cholangiocarcinoma was shown to be feasible in pilot studies of highly selected patients and genetic aberrations in brush cytology specimens should be explored further in prospective studies. Expand
A study of carboplatin‐coated tube for the unresectable cholangiocarcinoma
TLDR
A new percutaneous transhepatic biliary drainage tube coated with carboplatin (carboplatin‐coated tube; CCT) showed an antitumor effect on human cholangiocarcinoma cell line HuCC‐T1 in vitro and may provide a new treatment modality for this disease. Expand
Development of a therapeutic adenoviral vector for cholangiocarcinoma combining tumor-restricted gene expression and infectivity enhancement
TLDR
An adenoviral vector utilizing a tumor-specific promoter (TSP) for selective transgene expression and a vector with an RGD-motif in the fiber-knob region for infectivity enhancement have potential to overcome the obstacles to clinical application of adanoviral gene therapy in cholangiocarcinoma. Expand
Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study.
BACKGROUND & AIMS In nonrandomized trials, photodynamic therapy (PDT) had a promising effect on nonresectable cholangiocarcinoma (NCC). This prospective, open-label, randomized, multicenter studyExpand
MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma‐mass forming type
TLDR
Results suggest that expression of MUC4 in ICC‐MF is a new independent factor for poor prognosis and is a useful marker to predict the outcome of the patients with ICC‐ MF. Expand
Biliary cancer growth factor pathways, cyclo‐oxygenase‐2 and potential therapeutic strategies
TLDR
It is proposed that the selective therapeutic targeting of aberrant growth factor receptor tyrosine kinase signaling and of cyclo‐oxygenase‐2, alone or in combination, has potential to become a useful new approach for the treatment and/or chemoprevention of cholangiocarcinoma. Expand
Intrahepatic cholangiocarcinoma: indication for transplantation.
TLDR
Generally speaking, IH-CCC is not a favorable indication for liver transplantation, however, there is a highly selected group of patients with early tumor stages potentially benefitting from LTx, and combination with neoadjuvant chemoirradiation may further improve results after LTx. Expand
Mechanisms of biliary carcinogenesis: a pathogenetic multi-stage cascade towards cholangiocarcinoma.
TLDR
The known mechanisms involved in the carcinogenesis of biliary epithelium are addressed and established and hypothetical future therapeutic strategies directed towards specific pathogenetic events during biliary carcinogenesis will be addressed. Expand
COX-2 inhibition and colorectal cancer.
TLDR
Recent studies have identified a potential benefit for adding celecoxib to standard CRC chemotherapy regimens to increase their efficacy and reduce their associated toxicity. Expand
...
1
2
3
4
5
...